Assenagon Asset Management S.A. Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Assenagon Asset Management S.A. increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 2.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,350,925 shares of the company’s stock after purchasing an additional 38,446 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Stoke Therapeutics were worth $14,901,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of STOK. Lynx1 Capital Management LP increased its position in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. RTW Investments LP boosted its stake in shares of Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares during the period. State Street Corp boosted its stake in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Stoke Therapeutics by 550.1% in the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after purchasing an additional 982,451 shares during the period.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The shares were sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now directly owns 21,476 shares of the company’s stock, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

STOK has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Chardan Capital assumed coverage on Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 price objective on the stock. Leerink Partners started coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $9.36 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $4.09 and a 1 year high of $17.58. The stock has a market cap of $495.80 million, a price-to-earnings ratio of -4.46 and a beta of 0.95. The firm’s 50-day moving average is $11.58 and its two-hundred day moving average is $12.92.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.